Enisamium Inhibits SARS-CoV-2 RNA Synthesis.

TitleEnisamium Inhibits SARS-CoV-2 RNA Synthesis.
Publication TypeJournal Article
Year of Publication2021
AuthorsElli, S, Bojkova, D, Bechtel, M, Vial, T, Boltz, D, Muzzio, M, Peng, X, Sala, F, Cosentino, C, Goy, A, Guerrini, M, Müller, L, Cinatl, J, Margitich, V, Velthuis, AJWTe
Date Published2021/09/17

Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called coronavirus disease 2019 (COVID-19). While control of the SARS-CoV-2 spread partly depends on vaccine-induced or naturally acquired protective herd immunity, antiviral strategies are still needed to manage COVID-19. Enisamium is an inhibitor of influenza A and B viruses in cell culture and clinically approved in countries of the Commonwealth of Independent States. In vitro, enisamium acts through metabolite VR17-04 and inhibits the activity of the influenza A virus RNA polymerase. Here we show that enisamium can inhibit coronavirus infections in NHBE and Caco-2 cells, and the activity of the SARS-CoV-2 RNA polymerase in vitro. Docking and molecular dynamics simulations provide insight into the mechanism of action and indicate that enisamium metabolite VR17-04 prevents GTP and UTP incorporation. Overall, these results suggest that enisamium is an inhibitor of SARS-CoV-2 RNA synthesis in vitro.

Alternate JournalBiomedicines
PubMed ID34572438
PubMed Central IDPMC8467925
Grant List206579/Z/17/Z / / Wellcome /
10430 01 201 0018 / ZONMW_ / ZonMw / Netherlands